GlassScriptPhysician profile
Phillip A Boccagno
NPI 1639159510
$19,101.32
in general payments reported to CMS, 2019-2025
51 companies · $3,196 in 2025
The $3,196 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,902 · 2020: $1,738 · 2021: $2,329 · 2022: $2,749 · 2023: $3,273 · 2024: $2,914 · 2025: $3,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,384.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,310.90 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $2,286.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,124.71 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $1,683.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $1,073.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $848.63 | 2019-2025 | |
| Lilly USA, LLC | $798.87 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $725.04 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.39 | 2019-2024 | Jardiance, Tradjenta, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $632.93 | 2019-2025 | Xifaxan |
| Daiichi Sankyo INC. | $592.33 | 2019-2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $395.52 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Abbott Laboratories | $379.72 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $372.14 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Janssen Pharmaceuticals, INC | $338.33 | 2019-2023 | Xarelto |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Boccagno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.